nevanac
novartis europharm limited - nepafenak - pain, postoperative; ophthalmologic surgical procedures - augnlækningar - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.
pro-epanutin stungulyf, lausn/innrennslisþykkni, lausn 50 mg fe/ml
pfizer aps - fosphenytoinum dínatríum - stungulyf, lausn/innrennslisþykkni, lausn - 50 mg fe/ml
flutiform (affilia) innúðalyf, dreifa 125 míkróg/5 míkróg
mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 125 míkróg/5 míkróg
flutiform (affilia) innúðalyf, dreifa 250 míkróg/10 míkróg
mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 250 míkróg/10 míkróg
flutiform (affilia) innúðalyf, dreifa 50 míkróg/5 míkróg
mundipharma a/s - fluticasonum própíónat; formoterolum fúmarat - innúðalyf, dreifa - 50 míkróg/5 míkróg
fluticasone alvogen (nasofan) nefúði, dreifa 50 míkróg/skammt
alvogen ehf. - fluticasonum própíónat - nefúði, dreifa - 50 míkróg/skammt
cisordinol filmuhúðuð tafla 10 mg
h. lundbeck a/s* - zuclopenthixolum díhýdróklóríð - filmuhúðuð tafla - 10 mg
cisordinol filmuhúðuð tafla 2 mg
h. lundbeck a/s* - zuclopenthixolum díhýdróklóríð - filmuhúðuð tafla - 2 mg
cisordinol depot stungulyf, lausn 200 mg/ml
h. lundbeck a/s* - zuclopenthixolum decanóat - stungulyf, lausn - 200 mg/ml
cisordinol-acutard stungulyf, lausn 50 mg/ml
h. lundbeck a/s* - zuclopenthixolum acetas - stungulyf, lausn - 50 mg/ml